The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Mandrake (MAN) secures a “large-scale” lithium project in the Paradox Basin in Utah, US
  • The company says the 226 sqkm area lies in a region that contains “significant” concentrations of lithium, boron, potassium salts and other elements
  • Mandrake plans to compile existing geological and petrophysical data to generate a lithium exploration target in the short term and work towards a resource estimate in the second half of the year
  • The company says the US government “aggressively” promotes domestic critical minerals exploration through various funding and grants schemes
  • Mandrake shares are up 11.32 per cent and trading at 5.9 cents at 3:18 pm AEDT

Mandrake Resources (MAN) has secured a “large-scale” lithium project in the Paradox Basin in Utah, US.

The company has been granted a 226 sqkm area in a region it said contained “significant” concentrations of lithium, boron, potassium salts and other elements.

Mandrake plans to compile existing geological and petrophysical data to generate a lithium exploration target in the short term and work towards a maiden resource estimate in the second half of this year

“Utah is among the most mining- and investment-friendly jurisdictions in the US, with the state government heavily involved in aiding Utah-based projects to play a role in the global energy transition from fossil fuels to renewable energy,” Mandrage Managing Director James Allchurch said.

As Mandrake works to get exploration underway in the new area, ASX-listed lithium developer Galan Lithium (GLN) will provide technical support and an investment of $1.5 million in return for a five per cent stake in Mandrake.

The Paradox Basin lies in south-eastern Utah and has been historically documented to contain significant concentrations of strategic and critical minerals.

Mandrake shares were up 11.32 per cent and trading at 5.9 cents at 3:18 pm AEDT.

MAN by the numbers
More From The Market Online
A patient being dosed with Imugene Limited testing materials.

First Aussie doses bring Imugene major step closer to ‘quicker, cheaper’ non-Hodgkin’s lymphoma care

Imugene Limited (ASX:IMU) has hit its first important milestone in 2025, dosing its first Australian patient with its allogenic
A market trading board with ASX marked on the side.

‘Shine a light’: ASX to get more aggressive on companies ‘not up to scratch’ on disclosures

The Australian Securities Exchange (ASX:ASX) will be taking poor disclosure from market-listed companies far more seriously through this next
The words "Market Open" appear stacked atop one another next to ASX company iconography.

ASX Market Open: Ever-extending US loss streak to bleed into red Friday – unless Oz bucks trend again | Jan 3, 2024

The ASX 200 is expected to open 0.07% lower at 8,185 points, though after
Market Close Graphic

ASX Market Close: Bourse defies red futures to end up on 2025’s first trading day | Jan 2, 2024

The local bourse has defied morning predictions to end 34 points up, at 8,189 (a 0.44% gain) after ASX 200 futures originally suggested...